Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 290

Similar articles for PubMed (Select 20031832)

1.

Cardiovascular risks of nonsteroidal antiinflammatory drugs in patients after hospitalization for serious coronary heart disease.

Ray WA, Varas-Lorenzo C, Chung CP, Castellsague J, Murray KT, Stein CM, Daugherty JR, Arbogast PG, García-Rodríguez LA.

Circ Cardiovasc Qual Outcomes. 2009 May;2(3):155-63. doi: 10.1161/CIRCOUTCOMES.108.805689. Epub 2009 May 5.

3.

Non-aspirin NSAIDs, cyclooxygenase-2 inhibitors and risk for cardiovascular events-stroke, acute myocardial infarction, and death from coronary heart disease.

Roumie CL, Choma NN, Kaltenbach L, Mitchel EF Jr, Arbogast PG, Griffin MR.

Pharmacoepidemiol Drug Saf. 2009 Nov;18(11):1053-63. doi: 10.1002/pds.1820.

PMID:
19637402
5.

Risk of upper gastrointestinal complications associated with cyclooxygenase-2 selective and nonselective nonsteroidal antiinflammatory drugs.

Castellsague J, Holick CN, Hoffman CC, Gimeno V, Stang MR, Perez-Gutthann S.

Pharmacotherapy. 2009 Dec;29(12):1397-407. doi: 10.1592/phco.29.12.1397.

PMID:
19947799
6.

Association between nonnaproxen NSAIDs, COX-2 inhibitors and hospitalization for acute myocardial infarction among the elderly: a retrospective cohort study.

Rahme E, Watson DJ, Kong SX, Toubouti Y, LeLorier J.

Pharmacoepidemiol Drug Saf. 2007 May;16(5):493-503.

PMID:
17086567
8.

Rofecoxib, but not celecoxib, increases the risk of thromboembolic cardiovascular events in young adults-a nationwide registry-based study.

Gudbjornsson B, Thorsteinsson SB, Sigvaldason H, Einarsdottir R, Johannsson M, Zoega H, Halldorsson M, Thorgeirsson G.

Eur J Clin Pharmacol. 2010 Jun;66(6):619-25. doi: 10.1007/s00228-010-0789-2. Epub 2010 Feb 16.

PMID:
20157701
9.

Non-steroidal antiinflammatory drugs and the risk of acute myocardial infarction.

Hernández-Díaz S, Varas-Lorenzo C, García Rodríguez LA.

Basic Clin Pharmacol Toxicol. 2006 Mar;98(3):266-74.

PMID:
16611201
10.

Patients exposed to rofecoxib and celecoxib have different odds of nonfatal myocardial infarction.

Kimmel SE, Berlin JA, Reilly M, Jaskowiak J, Kishel L, Chittams J, Strom BL.

Ann Intern Med. 2005 Feb 1;142(3):157-64.

PMID:
15684203
11.

Risk of death or reinfarction associated with the use of selective cyclooxygenase-2 inhibitors and nonselective nonsteroidal antiinflammatory drugs after acute myocardial infarction.

Gislason GH, Jacobsen S, Rasmussen JN, Rasmussen S, Buch P, Friberg J, Schramm TK, Abildstrom SZ, Køber L, Madsen M, Torp-Pedersen C.

Circulation. 2006 Jun 27;113(25):2906-13. Epub 2006 Jun 19.

12.

Risk of hospitalization for myocardial infarction among users of rofecoxib, celecoxib, and other NSAIDs: a population-based case-control study.

Johnsen SP, Larsson H, Tarone RE, McLaughlin JK, Nørgård B, Friis S, Sørensen HT.

Arch Intern Med. 2005 May 9;165(9):978-84.

PMID:
15883235
13.

Quantitative assessment of the gastrointestinal and cardiovascular risk-benefit of celecoxib compared to individual NSAIDs at the population level.

Varas-Lorenzo C, Maguire A, Castellsague J, Perez-Gutthann S.

Pharmacoepidemiol Drug Saf. 2007 Apr;16(4):366-76.

PMID:
16897817
14.

Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults.

Solomon DH, Schneeweiss S, Glynn RJ, Kiyota Y, Levin R, Mogun H, Avorn J.

Circulation. 2004 May 4;109(17):2068-73. Epub 2004 Apr 19.

15.

[Are there any differences in the cardiovascular tolerance between classical NSAIDs and coxibs?].

Valat JP, Deray G, Héloire F.

Presse Med. 2006 Sep;35(9 Spec No 1):1S25-34. Review. French.

PMID:
17078592
16.

[What do we know about the cardiovascular toxicity of the NSAIDs?].

Sibilia J, Deray G, Montalescot G.

Presse Med. 2006 Sep;35(9 Spec No 1):1S11-23. Review. French.

PMID:
17078591
17.

Cardiovascular outcomes in new users of coxibs and nonsteroidal antiinflammatory drugs: high-risk subgroups and time course of risk.

Solomon DH, Avorn J, Stürmer T, Glynn RJ, Mogun H, Schneeweiss S.

Arthritis Rheum. 2006 May;54(5):1378-89.

18.

The risk of acute myocardial infarction with etodolac is not increased compared to naproxen: a historical cohort analysis of a generic COX-2 selective inhibitor.

Warner JJ, Weideman RA, Kelly KC, Brilakis ES, Banerjee S, Cunningham F, Harford WV, Kazi S, Little BB, Cryer B.

J Cardiovasc Pharmacol Ther. 2008 Dec;13(4):252-60. doi: 10.1177/1074248408323136. Epub 2008 Sep 11.

PMID:
18787084
19.

Cost of heart failure among hypertensive users of nonspecific NSAIDs and COX-2-specific inhibitors.

Zhao SZ, Burke TA, Whelton A, von Allmen H, Henderson SC.

Am J Manag Care. 2002 Oct;8(15 Suppl):S414-27.

20.

Cardiovascular risk of selective cyclooxygenase-2 inhibitors and other non-aspirin non-steroidal anti-inflammatory medications.

Velentgas P, West W, Cannuscio CC, Watson DJ, Walker AM.

Pharmacoepidemiol Drug Saf. 2006 Sep;15(9):641-52.

PMID:
16392153
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk